Article thumbnail
Location of Repository

APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts

By Kate N. Bishop, Mohit Verma, Eun-Young Kim, Steven M. Wolinsky and Michael H. Malim

Abstract

APOBEC3G (A3G) is a host cytidine deaminase that, in the absence of Vif, restricts HIV-1 replication and reduces the amount of viral DNA that accumulates in cells. Initial studies determined that A3G induces extensive mutation of nascent HIV-1 cDNA during reverse transcription. It has been proposed that this triggers the degradation of the viral DNA, but there is now mounting evidence that this mechanism may not be correct. Here, we use a natural endogenous reverse transcriptase assay to show that, in cell-free virus particles, A3G is able to inhibit HIV-1 cDNA accumulation not only in the absence of hypermutation but also without the apparent need for any target cell factors. We find that although reverse transcription initiates in the presence of A3G, elongation of the cDNA product is impeded. These data support the model that A3G reduces HIV-1 cDNA levels by inhibiting synthesis rather than by inducing degradation

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2584787
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
  2. (2007). Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
  3. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
  4. (2006). Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
  5. (2007). APOBEC-mediated viral restriction: not simply editing?
  6. (2007). APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
  7. (2006). APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
  8. (2007). APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
  9. (2008). APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog 4:
  10. (2006). APOBEC3G DNA deaminase acts processively 39R59 on single-stranded DNA.
  11. (2007). APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
  12. (2005). APOBECmediated interference with hepadnavirus production.
  13. (2006). Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.
  14. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
  15. (2005). Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
  16. (2006). Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
  17. (2008). Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins.
  18. (2008). Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.
  19. (2005). Complementary function of the two catalytic domains of APOBEC3G.
  20. (2007). Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
  21. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
  22. (2007). Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
  23. (2007). Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
  24. (2003). DNA deamination mediates innate immunity to retroviral infection.
  25. (1993). Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.
  26. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
  27. (1996). Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: An important stage for viral infection of nondividing cells.
  28. (2007). Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
  29. (2005). GRA hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.
  30. (1994). GRA hypermutation of the human immunodeficiency virus type 1 genome: Evidence for dCTP pool imbalance during reverse transcription.
  31. (2008). HIV-1 accessory proteins—Ensuring viral survival in a hostile environment.
  32. Hope TJ (2008) APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.
  33. (2008). Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1.
  34. (2007). Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
  35. (2001). Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.
  36. (2008). Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.
  37. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
  38. (2004). Inhibition of hepatitis B virus replication by APOBEC3G.
  39. (2007). Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.
  40. (2006). Inhibition of tRNAlysprimed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
  41. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
  42. (2007). Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
  43. (1995). Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.
  44. (2008). Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
  45. (2000). Role of Vif in stability of the human immunodeficiency virus type 1 core.
  46. (2004). Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
  47. (2008). Single-stranded RNA facilitates nucelocapsid:APOBEC3G complex formation.
  48. (1980). Skalka A
  49. (2003). Speciesspecific exclusion of APOBEC3G from HIV-1 virions by Vif.
  50. (2007). T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.
  51. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
  52. (2008). The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
  53. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
  54. (2008). The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
  55. (1996). The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.
  56. (2007). The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.
  57. (2006). Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
  58. (1993). Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.